Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT06226454
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT06185764
- Locations
- 🇺🇸
Stanford Neuromuscular Research, San Carlos, California, United States
🇺🇸University of Florida Clinical Research Center, Gainesville, Florida, United States
🇺🇸University of Kansas Medical Center, Fairway, Kansas, United States
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 218
- Registration Number
- NCT06176196
- Locations
- 🇺🇸
ARSN-Brain and Spine Institute, Port Orange, Florida, United States
🇺🇸Hope Research Institute, Phoenix, Arizona, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 255
- Registration Number
- NCT06154447
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 21
- Registration Number
- NCT05955872
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype
- Conditions
- Sickle Cell Disease
- Interventions
- Biological: Exa-cel
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT05951205
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT05882357
- Locations
- 🇦🇺
Telethon Kids Institute, Nedlands, Australia
🇦🇺The Royal Children's Hospital, Parkville, Australia
🇦🇺Queensland Children's Hospital, South Brisbane, Australia
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 56
- Registration Number
- NCT05867147
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 30
- Registration Number
- NCT05866055
- Locations
- 🇬🇧
PAREXEL International, Harrow, United Kingdom
A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
- Conditions
- Renal Impairment
- Interventions
- Drug: IXP
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT05865171
- Locations
- 🇺🇸
GCP Research, Ocala, Florida, United States
🇺🇸Genesis Clinical Research, Tampa, Florida, United States